150 related articles for article (PubMed ID: 25167922)
21. DAB2IP down-regulates HSP90AA1 to inhibit the malignant biological behaviors of colorectal cancer.
Zhang M; Peng Y; Yang Z; Zhang H; Xu C; Liu L; Zhao Q; Wu J; Wang H; Liu J
BMC Cancer; 2022 May; 22(1):561. PubMed ID: 35590292
[TBL] [Abstract][Full Text] [Related]
22. PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis.
Hu XF; Li J; Vandervalk S; Wang Z; Magnuson NS; Xing PX
J Clin Invest; 2009 Feb; 119(2):362-75. PubMed ID: 19147983
[TBL] [Abstract][Full Text] [Related]
23. DNA binding, cleavage and cytotoxicity studies of three mononuclear Cu(II) chloro-complexes containing N-S donor Schiff base ligands.
Parsekar SU; Fernandes J; Banerjee A; Chouhan OP; Biswas S; Singh M; Mishra DP; Kumar M
J Biol Inorg Chem; 2018 Dec; 23(8):1331-1349. PubMed ID: 30302601
[TBL] [Abstract][Full Text] [Related]
24. PML/RARA inhibits expression of HSP90 and its target AKT.
Piredda ML; Gaur G; Catalano G; Divona M; Banella C; Travaglini S; Puzzangara MC; Voso MT; Lo-Coco F; Noguera NI
Br J Haematol; 2019 Mar; 184(6):937-948. PubMed ID: 30536958
[TBL] [Abstract][Full Text] [Related]
25. Thiosemicarbazone Cu(II) and Zn(II) complexes as potential anticancer agents: syntheses, crystal structure, DNA cleavage, cytotoxicity and apoptosis induction activity.
Shao J; Ma ZY; Li A; Liu YH; Xie CZ; Qiang ZY; Xu JY
J Inorg Biochem; 2014 Jul; 136():13-23. PubMed ID: 24690556
[TBL] [Abstract][Full Text] [Related]
26. Higenamine enhances the antitumor effects of cucurbitacin B in breast cancer by inhibiting the interaction of AKT and CDK2.
Jin ZQ; Hao J; Yang X; He JH; Liang J; Yuan JW; Mao Y; Liu D; Cao R; Wu XZ; Li X; Chen D
Oncol Rep; 2018 Oct; 40(4):2127-2136. PubMed ID: 30106443
[TBL] [Abstract][Full Text] [Related]
27. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
28. Copper complex derived from S-benzyldithiocarbazate and 3-acetylcoumarin induced apoptosis in breast cancer cell.
Foo JB; Low ML; Lim JH; Lor YZ; Zainol Abidin R; Eh Dam V; Abdul Rahman N; Beh CY; Chan LC; How CW; Tor YS; Saiful Yazan L
Biometals; 2018 Aug; 31(4):505-515. PubMed ID: 29623473
[TBL] [Abstract][Full Text] [Related]
29. CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.
Xu XL; Bao QC; Jia JM; Liu F; Guo XK; Zhang MY; Wei JL; Lu MC; Xu LL; Zhang XJ; You QD; Sun HP
Sci Rep; 2016 Jan; 6():19004. PubMed ID: 26743233
[TBL] [Abstract][Full Text] [Related]
30. Folate-functionalized human serum albumin carrier for anticancer copper(II) complexes derived from natural plumbagin.
Gou Y; Zhang Z; Qi J; Liang S; Zhou Z; Yang F; Liang H
J Inorg Biochem; 2015 Dec; 153():13-22. PubMed ID: 26398432
[TBL] [Abstract][Full Text] [Related]
31. Interactions of Cu(I) with selenium-containing amino acids determined by NMR, XAS, and DFT studies.
Wang HC; Riahi M; Pothen J; Bayse CA; Riggs-Gelasco P; Brumaghim JL
Inorg Chem; 2011 Nov; 50(21):10893-900. PubMed ID: 21999616
[TBL] [Abstract][Full Text] [Related]
32. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
[TBL] [Abstract][Full Text] [Related]
33. Novel selenosemicarbazone metal complexes exert anti-tumor effect via alternative, caspase-independent necroptotic cell death.
Zec M; Srdic-Rajic T; Krivokuca A; Jankovic R; Todorovic T; Andelkovic K; Radulovic S
Med Chem; 2014; 10(8):759-71. PubMed ID: 24678785
[TBL] [Abstract][Full Text] [Related]
34. Influence of Complexation of Thiosemicarbazone Derivatives with Cu (II) Ions on Their Antitumor Activity against Melanoma Cells.
Pitucha M; Korga-Plewko A; Czylkowska A; Rogalewicz B; Drozd M; Iwan M; Kubik J; Humeniuk E; Adamczuk G; Karczmarzyk Z; Fornal E; Wysocki W; Bartnik P
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33803618
[TBL] [Abstract][Full Text] [Related]
35. Phosphorylation of DEPDC5, a component of the GATOR1 complex, releases inhibition of mTORC1 and promotes tumor growth.
Padi SKR; Singh N; Bearss JJ; Olive V; Song JH; Cardó-Vila M; Kraft AS; Okumura K
Proc Natl Acad Sci U S A; 2019 Oct; 116(41):20505-20510. PubMed ID: 31548394
[TBL] [Abstract][Full Text] [Related]
36. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.
Kim J; Roh M; Abdulkadir SA
BMC Cancer; 2010 Jun; 10():248. PubMed ID: 20515470
[TBL] [Abstract][Full Text] [Related]
37. FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation.
Huang W; Ye M; Zhang LR; Wu QD; Zhang M; Xu JH; Zheng W
Mol Cancer; 2014 Jun; 13():150. PubMed ID: 24927996
[TBL] [Abstract][Full Text] [Related]
38. Heat shock protein 90 inhibitor mycoepoxydiene modulates kinase signaling in cervical cancer cells and inhibits in-vivo tumor growth.
Lin P; Yi Y; Lu M; Wang M; Yang Y; Lu Y; Song S; Zheng Z; Deng X; Zhang L
Anticancer Drugs; 2015 Jan; 26(1):25-34. PubMed ID: 25014191
[TBL] [Abstract][Full Text] [Related]
39. The heat shock protein 90 inhibitor SNX-2112 inhibits B16 melanoma cell growth in vitro and in vivo.
Liu KS; Ding WC; Wang SX; Liu Z; Xing GW; Wang Y; Wang YF
Oncol Rep; 2012 Jun; 27(6):1904-10. PubMed ID: 22447251
[TBL] [Abstract][Full Text] [Related]
40. Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922.
Wang CY; Guo ST; Wang JY; Yan XG; Farrelly M; Zhang YY; Liu F; Yari H; La T; Lei FX; Jin L; Zhang XD; Jiang CC
Oncotarget; 2016 Aug; 7(31):49597-49610. PubMed ID: 27391062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
